Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 16/20 | 0.67 |
| ▸ | SLC22A12 | Q96S37 | 10/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19092950 | 0.99 | XDH (0.66) | XDHSLC22A12TP53MAPTRAB9A | |
| SCHEMBL17013372 | 0.91 | XDH (0.67) | XDHSLC22A12 | |
| SCHEMBL17941583 | 0.81 | XDH (0.67) | XDHSLC22A12 | |
| SCHEMBL20179459 | 0.81 | XDH (1.00) | XDHSLC22A12MAPTPOLB | |
| SCHEMBL17954725 | 0.80 | XDH (1.00) | XDHSLC22A12 | |
| SCHEMBL16700088 | 0.75 | XDH (1.00) | XDHSLC22A12MAPTPOLB | |
| SCHEMBL17013369 | 0.75 | XDH (0.65) | XDHSLC22A12 | |
| SCHEMBL17010232 | 0.74 | XDH (0.70) | XDHSLC22A12 | |
| SCHEMBL5265936 | 0.73 | NAMPT (0.66) | TP53MAPTRAB9AATMPOLB | |
| SCHEMBL17013273 | 0.73 | XDH (0.69) | XDHSLC22A12MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093631-B2 | Bifunctional compounds and use for reducing uric acid levels | ACQUIST LLC (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170197923-A1 | Bifunctional Compounds and Use for Reducing Uric Acid Levels | ACQUIST LLC | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197923-A1 | Bifunctional Compounds and Use for Reducing Uric Acid Levels | XDH, OAT, ATIC | XDH 1/4885SLC22A12 264/4885TP53 3903/4885 |
| US-10093631-B2 | Bifunctional compounds and use for reducing uric acid levels | XDH, OAT, ATIC | XDH 1/4885SLC22A12 264/4885TP53 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.